Recently, a combination therapy that consists of anti-PD-1 antibody and a multiple receptor tyrosine kinase inhibitor (Foretinib) was shown to significantly inhibit CRC tumor growth and relapse in mice, and to prolong overall survival [15]. Here, PDCD1 is linked to neoplasm.